MedTrace Logo

Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients

NCT00286377 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2006-02-03

No results posted yet for this study

Summary

This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to treat it.

Conditions

  • HIV
  • Peripheral Nervous System Disorders

Interventions

DRUG

prosaptide

Sponsors & Collaborators

  • Neurologic AIDS Research Consortium (NARC)

    collaborator OTHER

  • Savient Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Claudia Rehrig, MS · Savient Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2004-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00286377 on ClinicalTrials.gov